Corporate Actions

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 17, 2026, the Board of Directors (the “Board”) of National Health Investors, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, increased the size of the Board and appointed Lilly H. Donohue to fill the vacant seat, effective immediately, with an initial term expiring at the 2026 annual meeting of stockholders (the “2026 Annual Meeting”). Ms. Donohue has not been appointed to any committees of the Board at this time. Ms. Donohue is currently President and CEO of Everstory Partners (formerly StoneMor Inc.). Prior to joining Everstory Partners in November 2022, Ms. Donohue served as the CEO of Holiday Retirement, formerly the largest independent senior living owner and operator in the

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 17, 2026, the Compensation and Human Resources Committee of the Board of Directors (the “Board”) of Mueller Water Products, Inc. (the “Company”) recommended, and the Board approved, the appointment of Scott Floyd as the Company’s Executive Vice President and Chief Commercial Officer, effective February 23, 2026. This change resulted from the Company’s continued implementation of its management development and succession plans and is intended to continue to position the Company for long-term success. Mr. Floyd, age 56, has served as the Company’s Senior Vice President, Sales and Marketing since March 2024. He previously served as the Company’s Senior Vice President, Water Flow Solutions from October 2021 to March 2024, as Senior V

Entry into a Material Definitive Agreement On February 20, 2026 (the “Amendment Closing Date”), MoonLake Immunotherapeutics (the “Company”), as a guarantor, entered into a first amendment to loan and security agreement (the loan and security agreement, as so amended, the “Amended Loan and Security Agreement”) with its subsidiary, MoonLake Immunotherapeutics AG, as borrower, the other guarantors party thereto, the lenders party thereto (the “Lenders”), and Hercules Capital, Inc., as the administrative agent and collateral agent (the “Agent”) for itself and the Lenders, pursuant to which the parties agreed to amend the loan and security agreement dated March 31, 2025 to, among other things, modify the available tranches, milestone dates and financial covenants. As described below, after giving effect to a $25.0 million draw on the Amendment Closing Date, the remaining tranches under the A

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 17, 2026, Miluna Acquisition Corp (the “Company”) received a letter of resignation (the “Resignation Letter”) from Ms. Mei Chi Tsai. Pursuant to the Resignation Letter, Ms. Tsai resigned from her position as a member of the board of directors of the Company and from all the committees on which she served, effective February 17, 2026. The resignation of Ms. Tsai did not result from any dispute or disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. The Company has begun a process of identifying a qualified independent director to fill the vacancy created by Ms. Tsai’s resignation and intends to appoint a new independent director as soon as practicable. SIGNATURES Pursuant to the

Results of Operations and Financial Condition. On February 23, 2026, MediaAlpha, Inc. (“MediaAlpha” or the “Company”) issued a press release announcing its financial results as of and for the fourth quarter and full year ended December 31, 2025, and its financial outlook for the first quarter of 2026, and posted certain supplemental financial information to the Investor Relations section of its website. Copies of the press release and investor supplement are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Form 8-K and are incorporated by reference herein. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference i

Results of Operations and Financial Condition. On February 23, 2026, Myriad Genetics, Inc. announced its financial results for the three months ended December 31, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhibit 99.1, contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in Exhibit 99.1 to this Current Report on Form 8-K regarding these forward-looking statements. ITEM 9.01 Financial Statements and Exhibits. Exhibit Number Descrip

COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS On February 23, 2026, pursuant to the Equity and Asset Exchange Agreement, dated as of August 3, 2025 (the “Exchange Agreement”), by and between Martin Marietta Materials, Inc., a North Carolina corporation (“Martin Marietta”), and Quikrete Holdings, Inc., a Delaware corporation (“Quikrete”), (a) Martin Marietta transferred to Quikrete Martin Marietta’s assets primarily related to its cement and ready-mix concrete operations at its Midlothian cement plant and North Texas ready-mix concrete sites and certain nonoperating land, and (b) in exchange, Quikrete transferred to Martin Marietta Quikrete’s assets primarily related to its aggregates operations in Virginia, Missouri, Kansas and Vancouver, British Columbia along with $450 million in cash (the “Transaction”). The foregoing description of the Exchange Agreement in this Item 2.01 doe

Regulation FD Disclosure. On February 23, 2026, Mangoceuticals, Inc. (the “Company”, “we” and “us”) issued a press release announcing new data from field trials and a controlled study regarding its proprietary and patented antiviral compound MGX-0024, including zero respiratory-related mortality in approximately 29,000-bird commercial poultry field trials in India and prophylactic benefits against H5N1 in a government-conducted challenge study. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Secur

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 6, 2026, Lunai Bioworks Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined to delist the Company’s securities from Nasdaq. As previously disclosed, the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. On February 17, 2026, the Company received written notice from Nasdaq that the Panel has granted the Company’s request for a hearing. The hearing has been scheduled for March 26, 2026. As a result of the hearing request, the delisting action referenced in the Staff’s determination letter has been stayed pending a final written decision by the Panel. There can be no assurance tha

Entry into a Material Definitive Agreement. On February 17, 2026, Lument Finance Trust, Inc. (the “Company”), as borrower, and its subsidiaries, Five Oaks Acquisition Corp. and Lument CMT Equity, LLC, each as a guarantor (together, the “Guarantors”), Cortland Capital Market Services LLC, as the administrative agent and collateral agent (the “Agent”), and the lenders party thereto, entered into an amendment (the “Fifth Amendment”) to the Credit and Guaranty Agreement, dated January 15, 2019, as amended by each of the First Amendment to Credit and Guaranty Agreement, dated February 13, 2019, the Second Amendment to Credit and Guaranty Agreement, dated July 9, 2020, the Third Amendment to Credit and Guaranty Agreement, dated April 21, 2021, the Amended and Restated Third Amendment to Credit and Guaranty Agreement, dated August 23, 2021, and the Fourth Amendment to Credit and Guaranty Agree

Regulation FD Disclosure. On February 23, 2026, LQR House Inc. (the “Company”) issued a press release announcing the adjournment of its Special Meeting of Stockholders (the “Special Meeting”) and the reconvening of such meeting on March 2, 2026. The press release contains information about the Company’s view of its future expectations, plans and prospects that constitute forward-looking statements. A copy of the press release is furnished herewith as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as express

Results of Operations and Financial Condition. On February 23, 2026, Lincoln Educational Services Corporation. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 2.02 by reference. The information contained under this Item 2.02 in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. Furthermore, the information contained under this Item 2.02 in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be incorporated by reference into any registration statement or other docu

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 20, 2026, the Board of Directors (the “Board”) of Lakeland Industries, Inc. (the “Company”) appointed Lee D. Rudow as a Class I director of the Company, effective April 9, 2026. As a Class I director, Mr. Rudow’s term will expire at the Company’s 2026 Annual Meeting of Stockholders, at which time he will stand for election by the Company’s stockholders. In connection with such appointment, the Board determined that Mr. Rudow is independent within the meaning of the Nasdaq listing standards. With this appointment, the Board increased the size of the Board from seven members to eight members. The Board determined not to appoint Mr. Rudow to any Board committees at this time. Mr. Rudow has served as Chief Executive Officer of Transca

Results of Operations and Financial Condition. The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. On February 23, 2026, Keysight Technologies, Inc. (the “Company”) issued its press release announcing financial results for the first fiscal quarter ended January 31, 2026. A copy of this press release is attached hereto as Exhibit 99.1. We provide non-GAAP financial information in order to provide meaningful supplemental information regarding our operational performance and to enhance our investors’ overall understanding of our core current financial performance and our prospects for the future. We believe that our investors benefit

of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. The issuance and offering of the Convertible Preferred Stock will be undertaken in reliance upon an exemption from the registration requirements of Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The Convertible Preferred Stock issued pursuant to the Preferred Investment Agreement and the common stock, par value $0.01 per share, of KDP issuable upon conversion of the Convertible Preferred Stock may not be re-offered or sold in the United States absent an effective registration statement or an exemption from the registration requirements under applicable federal and state securities laws. Item 7.01 Regulation FD. On February 23, 2026, the Company issued a press release announcing the upsized Convertible Preferred Stock and the entry into the Transaction Agreement, among

Unregistered Sales of Equity Securities. On February 2, 2026, KKR FS Income Trust Select (the “Company”) issued and sold 1,004,296.392 Class I shares (the “Class I Shares”) of the Company’s common shares of beneficial interest (the “Shares”) (with the final number of Class I Shares issued being determined on February 23, 2026) pursuant to subscription agreements entered into with the participating investors for aggregate consideration of approximately $25.619 million. The offer and sale of the Class I Shares were conducted in connection with the Company’s continuous private offering of Shares (the “Private Offering”) in reliance on the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder. The Company relied, in part, upon representations

Unregistered Sales of Equity Securities. On February 2, 2026, KKR FS Income Trust (the “Company”) issued and sold 2,187,655.524 Class I shares (the “Class I Shares”) of the Company’s common shares of beneficial interest (the “Shares”) (with the final number of Class I Shares issued being determined on February 23, 2026) pursuant to subscription agreements entered into with the participating investors for aggregate consideration of approximately $64.885 million. The offer and sale of the Class I Shares were conducted in connection with the Company’s continuous private offering of Shares (the “Private Offering”) in reliance on the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder. The Company relied, in part, upon representations from ea

Regulation FD Disclosure. In accordance with General Instruction B.2. of Form 8-K, the following information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. On February 20, 2026, Kinder Morgan, Inc. (KMI) announced that representatives of KMI intend to participate in the following investor meetings to discuss the business and affairs of KMI: •Daniel Energy Partners Thrive Energy Conference on February 25, 2026 •Raymond James Institutional Investor Conference on March 3, 2026 •Morgan Stanley Energy & Power Conference on March 4, 2026 •Barclays Energy & Utilities Corporate Days on March 5, 2026 Materials to be used during the events will be available before 8:00 a.m. Central Time on February 23, 2026, on KMI’s website at:

Results of Operations and Financial Condition. The reconciliation schedule prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), which reconciles the non-GAAP financial measures to the most directly comparable GAAP financial measures and is included in Exhibit 99 to this Current Report on Form 8-K, is incorporated herein by reference into this Item 2.02. Item 7.01. Regulation FD Disclosure. On February 19, 2026, Kadant Inc. (the “Company,” “we,” or “our”) announced during its fourth quarter and full-year fiscal 2025 earnings webcast that it will prospectively use a new methodology for calculating adjusted operating income, adjusted net income, and adjusted earnings per share (“adjusted EPS”) (collectively, the “non-GAAP financial measures”) to exclude the full impact of amortization expense related to acquired intangible assets. Previously, the Company exc

Regulation FD Disclosure On February 23, 2026, JPMorgan Chase & Co. (“JPMorganChase” or the “Firm”) held a Company Update presentation during which it provided information to investors about the Firm. Exhibits 99.1, 99.2, and 99.3 are copies of the slides furnished at, and posted on the Firm’s website in connection with, the presentation. The slides are being furnished pursuant to Item 7.01, and the information contained therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities under that Section. Furthermore, the information contained in the Exhibits hereto shall not be deemed to be incorporated by reference into the filings of the Firm under the Securities Act of 1933. This Current Report on Form 8-K (including the Exhibits hereto) contains forward-looking statements within the meaning of the Private

Entry into a Material Definitive Agreement. On February 17, 2026, Invest Green Acquisition Corporation (the “Company”) issued an unsecured promissory note in the aggregate principal amount of $3,500,000 (the “Note”) to IG SPAC Sponsor LLC (“Sponsor”) that is effective as of December 1, 2025. Pursuant to the Note, the outstanding principal amount of the Note is payable on the date on which the Company consummates a business combination (the “Maturity Date”). At any time on or prior to the Maturity Date, Sponsor may elect to convert any amounts outstanding under the Note into units at a conversion price equal to $5.00 per unit (“Working Capital Units”). Each Working Capital Unit consists of one Class A ordinary share, par value $0.0001 per share (a “Working Capital Share”), and one right (a “Working Capital Right”), with each Working Capital Right entitling holder thereof to receive one-t

Other Events. On February 18, 2026, the board of directors of Invesco Ltd. (the “Company”) approved a share repurchase plan (the “2025 Share Repurchase Plan”) pursuant to which the Company may purchase up to an additional $1.0 billion in shares of the Company’s outstanding common stock, par value $0.20 per share (the “Common Stock”). The 2025 Share Repurchase Plan has no time limit or expiration date. The authorization under the 2025 Share Repurchase Plan is in addition to the Company’s existing share repurchase plan announced in July 2016 (the “2016 Share Repurchase Plan” and together with the 2025 Share Repurchase Plan, the “Share Repurchase Plans”). As of February 19, 2026, there remains approximately $213.4 million authorized under the 2016 Share Repurchase Plan. Under the Share Repurchase Plans, the Company may purchase Common Stock through open-market transactions, block or privat

Entry into a Material Definitive Agreement. Agreement and Plan of Merger On February 18, 2026, Interactive Strength Inc. (the "Company") entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Ergatta, Inc., a Delaware corporation ("Ergatta"), Ergatta Acquisition Corp., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Sub"), and Tom Aulet, solely in his capacity as the securityholders’ representative (the “Securityholders’ Representative”), pursuant to which Merger Sub will merge with and into Ergatta (the “Merger”), with Ergatta surviving as a wholly owned subsidiary of the Company. At the effective time of the Merger, each issued and outstanding share of preferred stock of Ergatta (other than excluded and dissenting shares) will be cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (i) cash cons

Regulation FD Disclosure. On February 23, 2026, Inhibrx Biosciences, Inc. (the “Company”) posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com. The presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. The Company from time to time presents and/or distributes the presentation to the investment community during conferences and meetings to provide updates and summaries of its business. The Company undertakes no obligation to update, supplement, or amend the materials attached hereto as Exhibit 99.1. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that sec

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On February 17, 2026, Jean S. Blackwell informed the Nominating & Governance Committee of the Board of Directors (the “Board”) of Ingevity Corporation (the “Company”) that she will not stand for election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Ms. Blackwell will continue to serve as a director through the date of the 2026 Annual Meeting. Her decision not to stand for election at the 2026 Annual Meeting did not result from any disagreement with the Company on any matter relating to its operations, policies or practices. Daniel F. Sansone will not stand for election at the 2026 Annual Meeting in accordance with the retirement age policy included in the Company’s Corporate Governance Guidelines. Upon the

Results of Operations and Financial Condition. On February 23, 2026, ImmunityBio, Inc. (the Company) issued a press release providing a business update and announcing its financial results for the fourth quarter and year ended December 31, 2025, and its financial position as of December 31, 2025. The full text of the Company’s press release is furnished as Exhibit 99.1 hereto. The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filings of the Company made under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, r

Entry Into a Material Definitive Agreement. The information contained in Item 3.02 of this Current Report on Form 8-K in relation to the Common Shares and the Warrants is incorporated herein by reference. Item 3.02 Unregistered Sale of Equity Securities. On February 23, 2026, the Company issued 26,427,053 Units (the “Units”) to EV Metals 9 LLC ("EV Metals"), an affiliate of EV Metals 7 LLC, in connection with a previously announced non-brokered private placement financing (the "Offering"), marking the third follow-on investment under the Company's previously announced binding Letter of Intent ("LOI") with EV Metals 7 LLC from March 2025. Each Unit includes one Company common share and one warrant (each, a "Warrant") to purchase one common share and is priced at USD $0.08 per Unit, with total gross proceeds of USD $2.0 million. Each Warrant entitles the holder to purchase one additional

Results of Operations and Financial Condition. On February 23, 2026, Innovative Industrial Properties, Inc. (the “Company”) issued a press release regarding its financial results for the fourth quarter ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. On February 23, 2026, the Company posted on its website, www.innovativeindustrialproperties.com, certain supplemental financial information for the fourth quarter ended December 31, 2025, which is attached hereto as Exhibit 99.2 and is incorporated by reference herein. Item 7.01 Regulation FD Disclosure. On February 23, 2026, the Company posted an investor presentation to its website located at http://investors.innovativeindustrialproperties.com. A copy of the investor presentation is attached hereto as Exhibit 99.3 and is incorporated by reference herein. The i

of the Company’s Current Report on Form 8-K filed with the SEC on December 8, 2025 is incorporated herein by reference. Item 1.01 Entry into a Material Definitive Agreement. Antero Upstream Purchase Agreement Amendment Under the Upstream Purchase Agreement, INR Holdings was to acquire an undivided 51% interest, and Northern was to acquire an undivided 49% interest, in the Upstream Assets. On February 22, 2026, the Buyers and Upstream Sellers entered into an amendment to the Upstream Purchase Agreement (the “Upstream Amendment”), pursuant to which, among other amendments, INR Holdings will acquire an undivided 60% interest, and Northern will acquire an undivided 40% interest, in the Upstream Assets. As a result of the Upstream Amendment, INR Holdings’ share of the unadjusted purchase price for the Upstream Assets is $480 million, and Northern’s share of the purchase price for the Upstrea

Entry into a Material Definitive Agreement. Commencing on February 16, 2026, I-On Digital Corporation (the “Company”) entered into settlement agreements (the “Agreements”) with five unrelated lenders to settle promissory notes (the “Notes”) in the aggregate, principal amount of $1,210,00 plus all interest, penalties and fees. Pursuant to the Agreement, the Notes were repaid and fully discharged in consideration for (i) the issuance of an aggregate of 396,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) 489.5 IONau gold-backed digital asset tokens issued by the Company. The IONau tokens were valued at approximately $2,454,304.05 in the aggregate, based on the closing spot price of gold of $5,013.90 per troy ounce on February 16, 2026. The valuation was derived from the contractually agreed methodology tied to the applicable LBMA referenc

Results of Operations and Financial Condition. On February 23, 2026, Hims & Hers Health, Inc. (the “Company”) issued a press release and a shareholder letter announcing its results of operations for the quarter and year ended December 31, 2025. Copies of the press release and the shareholder letter are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference in this Item 2.02. The information in this Current Report on Form 8-K and Exhibits 99.1 and 99.2 are being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as a

Changes in Registrant's Certifying Accountant. On February 19, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Healthcare Realty Trust Incorporated (the “Company”), elected to replace BDO USA, P.C. ("BDO") with Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm, effective as of February 19, 2026. BDO’s reports on the Company’s financial statements as of and for the years ended December 31, 2024 and 2025, did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles. During the fiscal years ended December 31, 2024 and 2025 and in the subsequent interim period through February 19, 2026, there were no "disagreements" as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions, between the C

Results of Operations and Financial Condition. On February 23, 2026, HealthStream, Inc. (the “Company”) issued a press release announcing results of operations for the fourth quarter and full year ended December 31, 2025 and provided guidance for the full year 2026, the text of which is set forth in Exhibit 99.1. Item 7.01 Regulation FD Disclosure On February 23, 2026, the Company issued a press release announcing results of operations for the fourth quarter and full year ended December 31, 2025 and provided guidance for the full year 2026, the text of which is set forth in Exhibit 99.1. Item 8.01 Other Events. On February 23, 2026, we announced that our Board of Directors declared a quarterly cash dividend under the Company's dividend policy in the amount of $0.035 per share of the Company’s outstanding common stock, which dividend will be payable on March 20, 2026 to holders of record

Other Events On February 13, 2026, HCM IV Acquisition Corp. (the “Company”) consummated its initial public offering (the “IPO”) of 28,750,000 units, including 3,750,000 units issued pursuant to the full exercise by the underwriter of its over-allotment option (the “Units”). Each Unit consists of one Class A ordinary share of the Company, par value $0.0001 per share (“Class A Ordinary Shares”), and one-quarter of one redeemable warrant of the Company (“Warrant”), with each whole Warrant entitling the holder thereof to purchase one Class A Ordinary Share for $11.50 per share. The Units were sold at a price of $10.00 per Unit. On February 11, 2026, simultaneously with the consummation of the IPO the Company completed the private sale (the “Private Placement”) of an aggregate of 4,666,667 warrants (the “Private Placement Warrants”) to HCM Investor Holdings IV, LLC (the “Sponsor”) and Cantor

Results of Operations and Financial Condition. On February 23, 2026, Great Lakes Dredge & Dock Corporation issued an earnings release announcing its financial results for the three and twelve months ended December 31, 2025. A copy of the earnings release is furnished as Exhibit 99.1 and incorporated herein by reference. The information in this Form 8-K and Exhibit 99.1 are furnished pursuant to Item 2.02 of this Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or incorporated by reference in any filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in any such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following exhibit is furnished herewith: 99.1 Earnings Release of Great Lakes Dredge & Dock Corporation dated Februa

Other Events. On February 23, 2026, Gossamer Bio, Inc. (the “Company” or “Gossamer”) announced topline results from its Phase 3 PROSERA study of seralutinib in patients with pulmonary arterial hypertension (PAH). Seralutinib is an investigational, inhaled tyrosine kinase inhibitor targeting PDGFR, CSF1R, and c-KIT, delivered via dry powder inhalation for the treatment of pulmonary arterial hypertension. The Phase 3 PROSERA Study enrolled 390 patients with WHO Functional Class (FC) II or III PAH, with 197 randomized to the seralutinib arm and 193 randomized to the placebo arm. 55% of the enrolled patients were on background triple or quadruple PAH therapy, and 61% were on background prostacyclin therapy. The treatment and placebo arms were generally well balanced. At Week 24, patients receiving seralutinib had a median change of +28.2 meters in 6MWD from baseline, while patients receivin

of this Form 8-K under the caption “Notes Offering” is incorporated herein by reference. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 4.1 Fourth Supplemental Indenture, dated as of November 24, 2025, relating to the 5.875% Notes due 2031, by and between the Company and Computershare Trust Company, National Association, as trustee. 4.2 Form of 5.875% Notes due 2031 (incorporated by reference to Exhibit 4.1 hereto). 4.3 Fifth Supplemental Indenture, dated as of February 23, 2026, relating to the 5.050% Notes due 2028, by and between the Company and Computershare Trust Company, National Association, as trustee. 4.4 Form of 5.050% Notes due 2028 (incorporated by reference to Exhibit 4.3 hereto). 4.5 Registration Rights Agreement, dated as of February 23, 2026, relating to the 5.875% Notes due 2031, by and between the Company and BofA Securities, Inc., as the representative of

Other Events. On February 23, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release in which it announced that the Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies to treat cancer. Also, the European Patent Office has issued a Decision to Grant relating to a patent for the combination of REQORSA and PD-1 antibodies to treat cancer. Genprex maintains an exclusive license to these patents. The granting of these patents in key markets will strengthen Genprex’s intellectual property portfolio, providing further protection for various therapeutic combinations, including the Acclaim-3 clinical trial for the treatment of small cell lung cancer using REQORSA in combination with PD-L1 antibodies. The press release further noted that these patents build upon Genprex’s ex

Results of Operations and Financial Condition. On February 23, 2026, GeneDx Holdings Corp. (the “Company”) issued a press release (the “Press Release”) and will hold a conference call announcing the Company's financial results for the year ended December 31, 2025. Copies of the Press Release and Earnings Presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information furnished with this Item 2.02, including Exhibits 99.1 and 99.2 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.0